← Leaderboards
Patrick Thomas McGann
Rhode Island Hospital
$3,173,320
Attributed
$3,705,131
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $897.6K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,705,131 · 5
By mechanism
U01$1,731,315 · 1
K23$910,194 · 1
R21$753,208 · 2
R33$310,414 · 1
Top collaborators
- Megan Song Mchenry3 shared
- Min Dong2 shared
Most similar at Rhode Island Hospital
Same institution · by research overlap
- Min Dong$364,055
- Roland C Merchant$12,559,068
- Sara Becker$17,765,703
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildAffectProspectiveMorbidity - Disease RateSickle Cell AnemiaLaboratoriesMeasurementInheritedHydroxyureaSafetyHematologyPharmaceutical PreparationsNational Heart, Lung, And Blood InstituteHematological DiseaseDoseAdultResearch StudyDrug KineticsChildhoodInterpatient VariabilityPreventMortalityLifeAfrica South Of The Sahara
Grant awards (16)
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa$240,266
U01 · FY2025 · HL · contact PI
Mobile phone-based screening for anemia in young children in western Kenya$221,547
R33 · FY2025 · HD · contact PI
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa$100,098
U01 · FY2025 · HL · contact PI
Mobile phone-based screening for anemia in young children in western Kenya$88,867
R33 · FY2025 · HD · contact PI
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa$340,364
U01 · FY2024 · HL · contact PI
Mobile phone-based screening for anemia in young children in western Kenya$383,192
R21 · FY2023 · HD · contact PI
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa$340,364
U01 · FY2023 · HL · contact PI
Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia$174,023
R21 · FY2023 · HD · contact PI
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa$340,364
U01 · FY2022 · HL · contact PI
Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia$195,993
R21 · FY2022 · HD · contact PI
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa$369,859
U01 · FY2021 · HL · contact PI
Therapeutic Response Evaluation and Adherence Trial: A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia$187,649
K23 · FY2019 · HL · contact PI
Therapeutic Response Evaluation and Adherence Trial: A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia$188,112
K23 · FY2018 · HL · contact PI
Therapeutic Response Evaluation and Adherence Trial: A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia$188,563
K23 · FY2017 · HL · contact PI
Therapeutic Response Evaluation and Adherence Trial: A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia$189,000
K23 · FY2016 · HL · contact PI
Therapeutic Response Evaluation and Adherence Trial: A Prospective Study of Hydroxyurea for Children with Sickle Cell Anemia$156,870
K23 · FY2015 · HL · contact PI